Last updated 5 days ago

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

416 patients around the world
Available in Brazil, Argentina, Belgium
Boehringer Ingelheim
7Research sites
416Patients around the world

This study is for people with

Renal disease
Chronic kidney disease

Requirements for the patient

From 18 Years
All Gender

Medical requirements

At least 18 years old and at least of the legal age of consent in countries where it is greater than 18 years.
Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
Male or female participants.
Woman of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per International Council on Harmonisation (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly.
For men, birth control is not required during the trial.
Evidence of Chronic Kidney Disease (CKD) at risk of progression based on two Estimated Glomerular Filtration Rate (eGFR) measurements recorded recently and at the time of Visit 1, with each Estimated Glomerular Filtration Rate (eGFR) ≥20 and <60 mL/min/1.73m2, irrespective of urine albumin creatinine ratio (UACR). The first of these measurements will be assessed from historical local laboratory results, and the second will be determined from serum creatinine analysed by the central laboratory at Visit 1.
Treatment with a clinically appropriate, stable dose of either Angiotensin-converting enzyme inhibitor (ACEi) or Angiotensin II Receptor Blockers (ARB) (but not both together) for ≥4 weeks before Visit 1, with no planned changes of the therapy for the duration of the trial.
Treatment with an SGLT2i within 4 weeks before Visit 2. Treatment with a sodium glucose co transporter 2 inhibitor (SGLT2i) should not be interrupted with the intention of enrolment into the trial.
Treatment with an mineralocorticoid receptor antagonist (MRA), aldosterone synthase inhibitor (ASi), or potassium-sparing diuretic(s) within 14 days prior to Visit 1. Requiring such treatment before randomisation, or planned during the trial, based on the judgment of the investigator. Treatment with an MRA or ASi should not be interrupted with the intention of enrolment into the trial.
Blood potassium of >5.2 mmol/L at Visit 1.
Blood Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) >3x Upper limit of normal (ULN) at Visit 1.
Known severe hepatic impairment (i.e. Child Pugh class C cirrhosis).
On dialysis, functioning kidney transplant, or scheduled for transplant.
Treated with new immunosuppression therapy for new or relapse/flare of pre-existing kidney disease within the last 60 days.
Currently treated with systemic mineralocorticoid replacement therapy (e.g. fludrocortisone).
Further exclusion criteria apply.

Sites

Instituto de Diagnóstico e Investigaciones Metabólicas - IDIM - sede centro - CABA
Instituto de Diagnóstico e Investigaciones Metabólicas - IDIM - sede centro - CABA
Libertad 836 - Libertad 836, Ciudad de Buenos Aires
Fundación Sanatorio Güemes - CABA, Buenos Aires
Fundación Sanatorio Güemes - CABA, Buenos Aires
Fco Acuña de Figueroa 1228
CEDIC Centro de Investigación Clínica - CABA, Buenos Aires
Jerónimo Salguero 2142, CABA, Buenos Aires
Instituto Medico Catamarca "IMEC"
Catamarca 2031, Rosario, Santa Fe
Centro Especialidades Médicas SRL (CEMEDIC)
Centro Especialidades Médicas SRL (CEMEDIC)
Ramón Falcón 5206, CABA, Buenos Aires
Mautalen - Salud e Investigación - CABA
Azcuénaga 1860, CABA, Buenos Aires
Fundação Faculdade Regional de Medicina de São José do Rio Preto
Av. Brg. Faria Lima, 5544 Sao Jose do Rio Preto - Estado de São Paulo 15090-000
LinkedinInstagramFacebook
Terms and ConditionsPrivacy Policy